MX9301530A - Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas. - Google Patents

Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas.

Info

Publication number
MX9301530A
MX9301530A MX9301530A MX9301530A MX9301530A MX 9301530 A MX9301530 A MX 9301530A MX 9301530 A MX9301530 A MX 9301530A MX 9301530 A MX9301530 A MX 9301530A MX 9301530 A MX9301530 A MX 9301530A
Authority
MX
Mexico
Prior art keywords
pirimidina
pirido
optionally substituted
agents
pyrimidine
Prior art date
Application number
MX9301530A
Other languages
English (en)
Spanish (es)
Inventor
Robert Alvarez
Robert S Wilhelm
Ronnie L Chin
Bruce H Devens
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of MX9301530A publication Critical patent/MX9301530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX9301530A 1992-03-20 1993-03-18 Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas. MX9301530A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/855,179 US5264437A (en) 1992-03-20 1992-03-20 Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones

Publications (1)

Publication Number Publication Date
MX9301530A true MX9301530A (es) 1994-01-31

Family

ID=25320543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301530A MX9301530A (es) 1992-03-20 1993-03-18 Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas.

Country Status (16)

Country Link
US (1) US5264437A (enExample)
EP (2) EP0631580A1 (enExample)
JP (1) JP3241384B2 (enExample)
KR (1) KR100274104B1 (enExample)
CN (1) CN1040327C (enExample)
AU (1) AU669520B2 (enExample)
CA (1) CA2132297C (enExample)
FI (1) FI106960B (enExample)
HU (2) HUT67552A (enExample)
IL (1) IL105092A (enExample)
MX (1) MX9301530A (enExample)
NO (1) NO301763B1 (enExample)
NZ (1) NZ251525A (enExample)
TW (1) TW240226B (enExample)
WO (1) WO1993019068A1 (enExample)
ZA (1) ZA931945B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996006843A1 (en) * 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
HUP9702408A3 (en) * 1995-02-10 2000-08-28 Schering Ag Use of 5-phenyloxazolidin-2-one derivatives for the preparation of pharmaceutical compositions treating diseases requiring tumour necrosis factor (tnf) inhibition
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JP2000119272A (ja) * 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd 新規7−アミノピリド〔2,3−d〕ピリミジン誘導体
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
TWI243055B (en) 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
AU2002363174B2 (en) * 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
CA2663401C (en) * 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
TW200835497A (en) * 2007-01-11 2008-09-01 Astrazeneca Ab Chemical compounds 636
WO2008084236A1 (en) * 2007-01-11 2008-07-17 Astrazeneca Ab Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
PT2297106E (pt) 2008-05-27 2014-09-29 Astrazeneca Ab Derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doença mediados por pde4
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
US20240400560A1 (en) * 2021-09-17 2024-12-05 Shionogi & Co., Ltd. Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
CN113831491B (zh) * 2021-09-30 2023-03-24 南昌大学 一种嘧啶唑共价有机框架的制备方法及吸附应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649917B2 (enExample) * 1973-12-18 1981-11-25
JPS58428B2 (ja) * 1974-07-05 1983-01-06 ヒサミツセイヤク カブシキガイシヤ シンキナ 2− オキソ −1,2,3,4− テトラヒドロピリド ( 2,3−d ) ピリミジンユウドウタイノ セイゾウホウ
DE2523730A1 (de) * 1974-06-12 1976-02-12 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidinonen
ATE63553T1 (de) * 1986-08-21 1991-06-15 Pfizer Chinazolindione und pyridopyrimidindione.
AU4220193A (en) * 1992-04-29 1993-11-29 Sri International Deazaaminopterins for treatment of inflammation

Also Published As

Publication number Publication date
IL105092A (en) 1998-06-15
JPH07504676A (ja) 1995-05-25
IL105092A0 (en) 1993-07-08
NZ251525A (en) 1996-09-25
JP3241384B2 (ja) 2001-12-25
HU9402653D0 (en) 1994-11-28
NO943456D0 (no) 1994-09-16
EP1770093A1 (en) 2007-04-04
ZA931945B (en) 1994-09-18
HUT67552A (en) 1995-04-28
WO1993019068A1 (en) 1993-09-30
FI944305L (fi) 1994-09-16
CA2132297C (en) 2006-01-03
US5264437A (en) 1993-11-23
AU669520B2 (en) 1996-06-13
NO301763B1 (no) 1997-12-08
CN1040327C (zh) 1998-10-21
FI106960B (fi) 2001-05-15
TW240226B (enExample) 1995-02-11
FI944305A0 (fi) 1994-09-16
NO943456L (no) 1994-09-16
EP0631580A1 (en) 1995-01-04
KR950700909A (ko) 1995-02-20
CN1078470A (zh) 1993-11-17
KR100274104B1 (ko) 2000-12-15
AU3918693A (en) 1993-10-21
HU210873A9 (en) 1995-08-28
CA2132297A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
MX2010006212A (es) Compuestos organicos.
NO301763B1 (no) Eventuelt substituerte pyrido-[2,3-d]-pyrimidin-2,4-(1H,3H)-dioner og pyrido-[2,3-d]pyrimidin-2-(1H,3H)-oner, anvendelse av slike for fremstilling av legemidler, samt farmasöytiske preparater inneholdende slike
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
MY123196A (en) 1,2,3-triazolo[4,5-d]pyrimidines as p2t receptor antagonists
AR014854A1 (es) POLIMORFO CRISTALINO DEL HIDROGENOSULFATO DE CLOPIDROGREL (FORMA2) (+)-(S)-ALFA-(2-CLOROFENIL)-4,5,6,7-TETRAHIDROTIENO[3,2-C]PIRIDINIL-5-ACETATO DE METILO ,PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA QUE LO CONTIENE
SI1017391T1 (sl) Formulacija tablete s podaljsanim sproscanjem za zdravljenje Parkinsonove bolezni
HU0103927D0 (en) Intermediates of pyrrolo[2,3-d]pyrimidine derivatives and process for the preparation thereof
PT1165558E (pt) Derivados de pirimido¬6,1-a|isoquinolina-4-ona
AR007855A1 (es) Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
AR007856A1 (es) Compuestos heterociclicos fusionados como inhibidores de proteina tirosina, quinasa, sus metodos de prepraracion, intermediarios, uso en medicina ycomposiciones farmaceuticas que los contienen
NO20075232L (no) Fremgangsmate for fremstilling av pyrido[2,3-d]pyrimidin-7-on og 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-on derivater
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
CA2239705A1 (en) Quinazoline-4-one ampa antagonists
IL177781A0 (en) Alkaloid formulations
WO2005044818A3 (en) Imidazo[1,2-a]pyridine anxiolytics
AP9901532A0 (en) 2-Methoxyphenylpiperazine derivatives.
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
MY143089A (en) Pyrido[2,3-d] pyrimidine derivatives, preparation thereof, therapeutic use thereof
SE0100297D0 (sv) New compounds
SE0100296D0 (sv) New compounds
MA71617A (fr) Formes cristallines de (6s,7s)-6-fluoro-7-(2-fluoro-5-méthylphényl)-3-(tétrahydro-2h-pyran-4-yl)-5,6,7,8-tétrahydropyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
ATE223412T1 (de) Antikonvulsiv und antiallergisch/antiasthmatisch wirkende pyrazolo(3,4-d)pyrimidine
ECSP992939A (es) Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmaceuticas
PA8470901A1 (es) Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmaceuticas
BRPI0516373A (pt) derivados de pirido(3,2-d)pirimidinas e uso dos mesmos

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees